# US 2014/0193393 A1 · Methods for Treatment of Stroke or Cerebrovascular Accidents Using an ETB Receptor Agonist > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 2014/0193393 A1 - Document ID: US20140193393A1 - Status: Published application - Kind: A1 - Application number: 14/149,785 - Filed: 2014-01-07 - Published: 2014-07-10 - Earliest claimed: 2007-08-21 - Assignees: Midwestern University - Applicants: Midwestern University - Inventors: ANIL GULATI - Web page: https://patentgrep.com/patent/US20140193393A1 ## CPC - C07K 14/47: from mammals - A61K 31/42: Oxazoles - A61K 38/1709: {from mammals} - A61K 38/1808: {Epidermal growth factor [EGF] urogastrone} - A61K 38/2285: {Endothelin, vasoactive intestinal contractor [VIC]} - A61K 38/49: Urokinase; Tissue plasminogen activator - A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca - A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis - C07K 14/57536: {Endothelin, vasoactive intestinal contractor [VIC]} - C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00) - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) - A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS ## Abstract Methods of using an ETB receptor agonist, such as IRL-1620, for the treatment of stroke or cerebrovascular accidents are disclosed. The ETB receptor agonist is used alone or in combination with a second agent useful in the treatment of stroke or other cerebrovascular accident. ## Claims ### Claim 1 A method of treating a stroke or cerebrovascular accident comprising administering a therapeutically effective amount of an ETB receptor agonist to an individual in need thereof. ### Claim 2 (depends on 1) The method of claim 1 wherein the stroke or cerebrovascular accident is caused by thrombosis, embolism, or hemorrhage. ### Claim 3 (depends on 1) The method of claim 1 wherein the ETB receptor agonist is selected from the group consisting of N-Succinyl-[Glu9, Ala11,15] Endothelin 1, ET-3, sarafotoxin 6c, N-Ac-Ala(11,15)-endothelin-1 (6-21), Ala(1, 3, 11, 15)ET-1, and mixtures thereof. ### Claim 4 (depends on 1) The method of claim 1 wherein the ETB receptor agonist comprises N-Succinyl-[Glu9, Ala11,15] Endothelin 1. ### Claim 5 (depends on 1) The method of claim 1 further comprising administering a therapeutically effective amount of a second therapeutic agent useful in the treatment of stroke or cerebrovascular accident. ### Claim 6 (depends on 5) The method of claim 5 wherein the second therapeutic agent comprises a neuroprotective agent. ### Claim 7 (depends on 6) The method of claim 6 wherein the neuroprotective agent is selected from the group consisting of a thrombolytic agent, an erythropoiesis-stimulating agent, an ETA antagonist, an oxygen carrier, and mixtures thereof. ### Claim 8 (depends on 7) The method of claim 7 wherein the thrombolytic agent comprises tissue plasminogen activator. ### Claim 9 (depends on 7) The method of claim 7 wherein the erythropoiesis-stimulating agent is selected from the group consisting of erythropoietin, darbepoetin, epoetin alfa, and mixtures thereof. ### Claim 10 (depends on 7) The method of claim 7 wherein the oxygen carrier comprises a hemoglobin-based blood substitute, a perfluorocarbon-based blood substitute, or a mixture thereof. ### Claim 11 (depends on 7) The method of claim 7 wherein the ETA antagonist is selected from sulfosoxazole, clazosentan, atrasentan, tezosentan, bosentan, sitaxsentan, enrasentan, BMS 207940, BMS 193884, BMS 182874, J 104132, VML 588/Ro 61 1790, T-0115, TAK 044, BQ 788, TBC2576, TBC3214, PD180988, ABT 546, SB247083, RPR118031A, BQ123, and mixtures thereof. ### Claim 12 (depends on 5) The method of claim 5 wherein the neuroprotective agent is selected from the group consisting of argatroban, alfimeprase, tenecteplase, ancrod, sildenafil, insulin, insulin growth factor, magnesium sulfate, human serum albumin, caffeinol, microplasmin, a statin, eptifibatide, tinzaparin, enecadin, citicoline, edaravone, cilostazol, hypothermia, and mixtures thereof. ### Claim 13 (depends on 5) The method of claim 5 wherein the ETB agonist and the second therapeutic agent are administered simultaneously. ### Claim 14 (depends on 13) The method of claim 13 wherein the ETB agonist and the second therapeutic agent are administered from a single composition. ### Claim 15 (canceled) ### Claim 16 (depends on 5) The method of claim 5 wherein the ETB agonist and the second therapeutic agent are administered separately. ### Claim 17 (depends on 16) The method of claim 16 wherein the ETB agonist is administered prior to the second therapeutic agent. ### Claim 18 (canceled) ### Claim 19 (depends on 1) The method of claim 1 wherein the ETB agonist is administered in an amount of about 0.005 to about 500 micrograms per dose. ### Claim 20 (depends on 1) The method of claim 1 wherein the ETB agonist is administered in an amount of about 0.005 to about 50 micrograms per kilogram per min infusion. ### Claim 21 A kit comprising: (a) a packaged composition comprising an ETB agonist; (b) optionally, a packaged composition comprising a second therapeutic agent useful in a treatment of stroke or other cerebrovascular accident, (c) an insert providing instructions for a simultaneous or sequential administration of (a), or (a) and (b), to treat the stroke or other cerebrovascular accident in a human; and (c) a container for (a), (b), and (c). ### Claim 22 (canceled) ### Claim 23 A composition comprising (a) an ETB agonist, (b) a neuroprotective agent, and (c) an optional excipient and/or pharmaceutically acceptable carrier.